Citations

Mayo Clinic

Clear

2329 citation(s) found for "D'Andrea, AD".

Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer
Mullany, Sally A., Kebria, Mehdi , Khurana, Ashwani, Clayton, Amy C., Ota, Takayo , Mariani, Andrea , Podratz, Karl C. , Chien, Jeremy , Shridhar, Viji , Rattan, Ramandeep , Chien, Jeremey

Clinical Cancer Research | November 24, 2010 | Volume: 17 | Issue: 3 | Pages: 427-436

10.1158/1078-0432.ccr-09-3069 | PMID 21098697 Get It

AbstractPurpose: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines.Experimental design: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones.Results: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016).Conclusions: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors. Clin Cancer Res; 17(3); 427–36. ©2010 AACR.
Cardiac Baroreflex Sensitivity Is Not Correlated to Sympathetic Baroreflex Sensitivity Within Healthy, Young Humans
Dutoit, Andrea P. , Hart, Emma C. , Charkoudian, Nisha , Wallin, B. Gunnar, Curry, Timothy B. , Joyner, Michael J. , Joyner, Michael J , Hart, Emma C

Hypertension | November 9, 2010 | Volume: 56 | Issue: 6 | Pages: 1118-1123

10.1161/hypertensionaha.110.158329 | PMID 21060001 Get It

The purpose of this study was to evaluate the relationship between the cardiac and sympathetic baroreflex sensitivities within healthy, young humans. The sensitivities of the cardiac and sympathetic baroreflexes were compared in 53 normotensive individuals (28 men and 25 women; age: 24.0±0.9 years; body mass index: 24.0±0.3 cm/kg 2 , mean±SEM). Heart rate, arterial blood pressure, and peroneal muscle sympathetic nerve activity were recorded under resting conditions (heart rate: 58±1 bpm; systolic blood pressure: 126±2 mm Hg; diastolic blood pressure: 72±1 mm Hg; mean arterial blood pressure: 89±1 mm Hg; muscle sympathetic nerve activity: 18±1 bursts per min) and during rapid changes in blood pressure induced by sequential boluses of nitroprusside and phenylephrine. Cardiac and sympathetic baroreflex sensitivities were analyzed using the slopes of the linear portions of the muscle sympathetic nerve activity-diastolic blood pressure and R-R interval-systolic blood pressure relationships, respectively. When individual cardiac baroreflex sensitivity was compared with sympathetic baroreflex sensitivity, no correlation (R-R interval: r =−0.13; heart rate: r =0.21) was observed when studied as a group. Analysis by sex unveiled a correlation in women between the cardiac and sympathetic baroreflex sensitivities (R-R interval: r =−0.54; P =0.01; no correlation with hazard ratio: r =0.29). No relationship was found in men (R-R interval: r =0.17; heart rate: r =0.12). These results indicate that, although both cardiac and sympathetic efferents function in baroreflex control of arterial pressure, there is no correlation in their sensitivities within healthy normotensive humans. However, sex-stratified data indicate that sex-based differential correlations might exist.
A Prospective Comparison of Cardiac Imaging Using Intracardiac Echocardiography With Transesophageal Echocardiography in Patients With Atrial Fibrillation
Saksena, Sanjeev , Sra, Jasbír , Jordaens, Luc , Knight, Bradley P. , Kocheril, Abraham G. , Nanda, Navin C. , Nagarakanti, Rangadham , Viggiano, Mary A., Chandler, Mary L., Group, ICE-CHIP Investigator Study, Kusumoto, Fred , Natale, Andrea , Simon, Ann M. , Lokhandwala, Tasneem , Group, ICE-CHIP Investigator Study, Knight, Bradley P

Circulation: Arrhythmia and Electrophysiology | September 18, 2010 | Volume: 3 | Issue: 6 | Pages: 571-577

10.1161/circep.110.936161 | PMID 20852299 Get It

Background— The Intracardiac Echocardiography Guided Cardioversion Helps Interventional Procedures study evaluated the concordance of intracardiac echocardiography (ICE) with transesophageal echocardiography (TEE) in patients with atrial fibrillation (AF). Methods and Results— Patients with AF undergoing right heart catheterization underwent left atrium (LA) and interatrial septal (IAS) imaging by TEE and ICE. A blinded comparison of the 2 modalities was performed at a core laboratory. Ninety-five patients aged 58±12 years completed the study. The LA was profiled in all patients with both techniques, and concordance for image quality was 96%. LA appendage (LAA) imaging was achieved in 85% with ICE and 96% with TEE. There was no difference in the presence of spontaneous echo contrast between ICE and TEE during LA imaging, but there was a trend toward a greater incidence in the LAA with TEE ( P =0.109). Intracardiac thrombus was uncommonly seen (TEE, 6.9%; ICE, 5.2%). The concordance for the presence or absence of thrombus was 97% in the LA and 92% in the LAA, but the latter was detected more frequently with TEE. IAS imaging was achieved in 91% with ICE and in 97% with TEE ( P =0.177). Concordance for patent foramen ovale and atrial septal aneurysms was 100% and 96%, respectively. A negative ICE examination was associated with absence of dense echo contrast or thrombus on TEE in 86%. Conclusions— This study provides validation for the use of ICE for LA and IAS imaging. ICE imaging was less sensitive compared to TEE for LAA thrombus identification. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00281073.
Insulin Receptor A and IGF-IR in AML – Response
Hendrickson, Andrea E. Wahner , Erlichman, Charles , Gottardis, Marco M. , Carboni, Joan M., Karp, Judith E. , Haluska, Paul , Kaufmann, Scott H.

Cancer Research | August 11, 2010 | Volume: 70 | Issue: 17 | Pages: 7010-7010

10.1158/0008-5472.can-10-1920 Get It

Combinatorial Chemoprevention Reveals a Novel Smoothened-Independent Role of GLI1 in Esophageal Carcinogenesis
DeMars, Cathrine J., Comba, Andrea , Gainullin, Vladimir G. , Rizvi, Zaheer H., Almada, Luciana L. , Lomberk, Gwen , Fernández-Zapico, Martín E. , Buttar, Navtej , Ilyas, Sumera I. , Wang, Kenneth , Lomberk, Gwen L

Cancer Research | July 20, 2010 | Volume: 70 | Issue: 17 | Pages: 6787-6796

10.1158/0008-5472.can-10-0197 | PMID 20647328 Get It

Abstract Reflux-induced injury promotes esophageal adenocarcinoma, one of the most rapidly increasing, highly lethal cancers in Western countries. Here, we investigate the efficacy of a combinatorial chemoprevention strategy for esophageal adenocarcinoma and characterize the underlying molecular mechanisms. Specifically, our approach involves the use of ursodeoxycholic acid (Urso) due to its ability to decrease injury-inducing bile salts in combination with Aspirin to mitigate the consequences of injury. We find that Urso-Aspirin combination reduces the risk of adenocarcinoma in vivo in animals with reflux, decreases the proliferation of esophageal adenocarcinoma cells, and downregulates a key cell cycle regulator, CDK2. Mechanistically, using cell growth, luciferase reporter, expression, and chromatin immunoprecipitation assays, we identify GLI1, a Hedgehog-regulated transcription factor, as a novel target of Urso-Aspirin combination. We show that GLI1 is upregulated during esophageal carcinogenesis, and GLI1 can bind to the CDK2 promoter and activate its expression. Although the Urso-Aspirin combination downregulates GLI1, the GLI1 overexpression not only abrogates the effect of this combination on proliferation but it also restores CDK-2 expression. These findings support that the chemopreventive effect of the Urso-Aspirin combination occurs, at least in part, through a novel GLI1-CDK2–dependent mechanism. To further understand the regulation of CDK2 by GLI1, both pharmacologic and RNAi-mediated approaches show that GLI1 is a transcriptional activator of CDK2, and this regulation occurs independent of Smoothened, the central transducer of the Hedgehog canonical pathway. Collectively, these results identify a novel GLI1-to-CDK2 pathway in esophageal carcinogenesis, which is a bona fide target for effective combinatorial chemoprevention with Urso and Aspirin. Cancer Res; 70(17); 6787–96. ©2010 AACR.
Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use
Cummings, Steve, Vachon, Celine M. , Vacek, Pamela M. , Miglioretti, Diana L. , Kerlikowske, Karla , Cook, Andrea J. , Buist, Diana S.M. , Vachon, Celine M. , Miglioretti, Diana L

Journal of Clinical Oncology | July 20, 2010 | Volume: 28 | Issue: 24 | Pages: 3830-3837

10.1200/jco.2009.26.4770 | PMID 20644098 Get It

Purpose We determined whether the association between breast density and breast cancer risk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT) use. Methods We collected data on 587,369 women who underwent 1,349,027 screening mammography examinations; 14,090 women were diagnosed with breast cancer. We calculated 5-year breast cancer risk from a survival model for subgroups of women classified by their Breast Imaging Reporting and Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body mass index of 25 kg/m 2 . Odds of advanced (ie, IIb, III, IV) versus early (ie, I, IIa) stage invasive cancer was calculated according to BIRADS density. Results Breast cancer risk was low among women with low density (BIRADS-1): women age 55 to 59 years, 5-year risk was 0.8% (95% CI, 0.6 to 0.9%) for non-HT users and 0.9% (95% CI, 0.7% to 1.1%) for estrogen and estrogen plus progestin users. Breast cancer risk was high among women with very high density (BIRADS-4), particularly estrogen plus progestin users: women age 55 to 59 years, 5-year risk was 2.4% (95% CI, 2.0% to 2.8%) for non-HT users, 3.0% (95% CI, 2.6% to 3.5%) for estrogen users, and 4.2% (95% CI, 3.7% to 4.6%) for estrogen plus progestin users. Advanced-stage breast cancer risk was increased 1.7-fold for postmenopausal HT users who had very high density (BIRADS-4) compared to those with average density (BIRADS-2). Conclusion Postmenopausal women with high breast density are at increased risk of breast cancer and should be aware of the added risk of taking HT, especially estrogen plus progestin.
P3‐193: The plasma Aβ42/Aβ40 ratio: A promising biomarker for cognitive decline
Weston, Andrea, Hou, Nanjiang, Graff‐Radford, Neill R. , Satterfield, Suzanne , Harris, Tamara B. , Kuller, Lewis H. , Ayonayon, Hilsa N., Dong, Jingzhong, Younkin, Linda H., Younkin, Steven G. , Yaffe, Kristine , Study, for the Health ABC, Simonsick, Eleanor Marie , Study, for the Health ABC

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_16 | Pages: No page available

10.1016/j.jalz.2010.05.1691 Get It

P2‐130: Anxiety is associated with mild cognitive impairment: The Mayo Clinic Study of Aging
Obermeier, Andrea A., Roberts, Rosebud O., Christianson, Teresa J., Rocca, Walter A. , Petersen, Ronald C. , Geda, Yonas E. , Knopman, David S. , Pankratz, V. Shane , Boeve, Bradley F.

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2010.05.1177 Get It

Mapping of Conformational Epitopes on Human Proteinase 3, the Autoantigen of Wegener’s Granulomatosis
Kuhl, Angelika, Korkmaz, Brice , Utecht, Bert, Kniepert, Andrea, Schönermarck, Ulf , Jenne, Dieter E. , Specks, Ulrich

The Journal of Immunology | June 8, 2010 | Volume: 185 | Issue: 1 | Pages: 387-399

10.4049/jimmunol.0903887 | PMID 20530264 Get It

Abstract Anti-neutrophil cytoplasmic Abs (cANCAs) against conformational epitopes of proteinase 3 (PR3) are regarded as an important pathogenic marker in Wegener’s granulomatosis (WG). Although the three-dimensional structure of PR3 is known, binding sites of mAbs and cANCAs have not been mapped to date. Competitive binding and biosensor experiments suggested the existence of four nonoverlapping areas on the PR3 surface. In this paper, we present an approach to identify these discontinuous surface regions that cannot be mimicked by linear peptides. The very few surface substitutions found in closely related PR3 homologs from primates, which were further varied by the construction of functional human-gibbon hybrids, resulted in the differential loss of three Ab binding sites, two of which were mapped to the N-terminal β-barrel and one to the linker segment connecting the N- and C-terminal barrels of PR3. The sera from WG patients differed in their binding to gibbon PR3 and the gibbon-human PR3 hybrid, and could be divided into two groups with similar or significantly reduced binding to gibbon PR3. Binding of almost all sera to PR3–α1-protease inhibitor (α1–PI) complexes was even more reduced and often absent, indicating that major antigenic determinants overlap with the active site surface on PR3 that associates with α1-PI. Similarly, the mouse mAbs CLB12.8 and 6A6 also did not react with gibbon PR3 and PR3–α1-PI complexes. Our data strongly suggest that cANCAs from WG patients at least in part recognize similar surface structures as do mouse mAbs and compete with the binding of α1-PI to PR3.
Infants of Women with Polycystic Ovary Syndrome Have Lower Cord Blood Androstenedione and Estradiol Levels
Anderson, Helen, Fogel, Naomi, Grebe, Stefan K., Dunaif, Andrea , Singh, Ravinder J. , Taylor, Robert L.

The Journal of Clinical Endocrinology & Metabolism | March 13, 2010 | Volume: 95 | Issue: 5 | Pages: 2180-2186

10.1210/jc.2009-2651 | PMID 20228162 Get It

Abstract Context: Prenatal androgen excess can cause a phenocopy of polycystic ovary syndrome (PCOS) in mammals. Retrospective studies have suggested that girls at risk for PCOS have low birth weight, and prospective studies have suggested an increased prevalence of small-for-gestational-age offspring in women with PCOS. Objective: The objective of the study was to determine whether infants of women with PCOS have reduced birth weight or increased intrauterine androgen levels. Design: This was a prospective case-control study. Participants: Thirty-nine PCOS and 31 control women and their infants participated in the study. Main Outcome Measures: Birth weight and mixed cord blood testosterone, androstenedione (A), dehydroepiandrosterone, 17-hydroxyprogesterone, estradiol (E2), and dihydrotestosterone levels were measured. Results: Mean birth weight did not differ, but there was a significant increase in the prevalence of large-for-gestational-age infants in the PCOS group. Cord blood E2 and A levels were lower (P < 0.05), but testosterone to E2 ratios did not differ in female PCOS compared with control offspring. There was no difference in E2 and A levels in the male PCOS and control offspring. There was no difference in 17-hydroxyprogesterone or other androgen levels in either male or female PCOS offspring compared with their respective control group. Conclusion: Infants of women with PCOS were more likely to be large for gestational age. Female offspring of affected women have lower cord blood A levels; other cord blood androgen levels do not differ compared with female control offspring. Cord blood E2 levels are also significantly decreased in PCOS, without any difference in the testosterone to E2 ratio, suggesting decreased fetal or placental production of steroids.